Allergy immunotherapy adherence and delivery route: Location does not matter

Journal of Allergy and Clinical Immunology: In Practice

Volumn 2, Issue 2, 2014, Pages

  Cox, Linda S ^a   Hankin, Cheryl ^b   Lockey, Richard ^c  

^a Allergy and Asthma Center   (United States)

^b BioMedicon   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGIC RHINITIS; ALLERGY IMMUNOTHERAPY; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; COST OF ILLNESS; EDITORIAL; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; IMMUNOTHERAPY; MEDICATION COMPLIANCE; NONHUMAN; PATIENT SAFETY; PATIENT SATISFACTION; REIMBURSEMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; TREATMENT RESPONSE;

DESENSITIZATION, IMMUNOLOGIC; HUMANS; PATIENT COMPLIANCE;

EID: 84895419503     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2014.01.010     Document Type: Editorial

References (105)

1. Baroody F.M. Allergic rhinitis: broader disease effects and implications for management. Otolaryngol Head Neck Surg 2003, 128:616-631.
2. Settipane R.A. Complications of allergic rhinitis. Allergy Asthma Proc 1999, 20:209-213.
3. Meltzer E.O., Blaiss M.S., Derebery M.J., et al. Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. JAllergy Clin Immunol 2009, 124(Suppl):S43-S70.
4. Allergies in America: A Landmark Survey of Nasal Allergy Sufferers. 2006. Available from: Accessed June 14, 2012. http://www.worldallergy.org/UserFiles/file/Findings%20for%20Adults,%20Full%20Results.pdf.
5. Schappert S.M., Rechtsteiner E.A. Ambulatory medical care utilization estimates for 2007. Vital Health Stat 13 2011, (169):1-38.
6. Nathan R.A. The burden of allergic rhinitis. Allergy Asthma Proc 2007, 28:3-9.
7. Eng P.A., Borer-Reinhold M., Heijnen I.A., Gnehm H.P. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006, 61:198-201.
8. Eng P.A., Reinhold M., Gnehm H.P. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002, 57:306-312.
9. Di Rienzo V., Marcucci F., Puccinelli P., Parmiani S., Frati F., Sensi L., et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003, 33:206-210.
10. Durham S.R., Emminger W., Kapp A., Colombo G., de Monchy J.G., Rak S., et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. JAllergy Clin Immunol 2010, 125. 131-8.e1-7.
11. Durham S.R., Emminger W., Kapp A., Monchy J.G., Rak S., Scadding G.K., et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. JAllergy Clin Immunol 2012, 129. 717-25.e5.
12. Tahamiler R., Saritzali G., Canakcioglu S. Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis. Laryngoscope 2007, 117:965-969.
13. Marogna M., Spadolini I., Massolo A., Canonica G.W., Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. JAllergy Clin Immunol 2010, 126:969-975.
14. Musarra A., Bignardi D., Troise C., Passalacqua G. Long-lasting effect of a monophosphoryl lipid-adjuvanted immunotherapy to Parietaria. A controlled field study. Eur Ann Allergy Clin Immunol 2010, 42:115-119.
15. Mosbech H., Osterballe O. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy 1988, 43:523-529.
16. Hedlin G., Heilborn H., Lilja G., Norrlind K., Pegelow K.O., Schou C., et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. JAllergy Clin Immunol 1995, 96:879-885.
17. Durham S.R., Walker S.M., Varga E.M., Jacobson M.R., O'Brien F., Noble W., et al. Long-term clinical efficacy of grass-pollen immunotherapy. NEngl J Med 1999, 341:468-475.
18. James L.K., Shamji M.H., Walker S.M., Wilson D.R., Wachholz P.A., Francis J.N., et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. JAllergy Clin Immunol 2011, 127. 509-16.e1-5.
19. Tabar A.I., Arroabarren E., Echechipia S., Garcia B.E., Martin S., Alvarez-Puebla M.J. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. JAllergy Clin Immunol 2011, 127:47-63.
20. Marogna M., Bruno M., Massolo A., Falagiani P. Long-lasting effects of sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial hyperreactivity: a long-term (13-year) retrospective study in real life. Int Arch Allergy Immunol 2007, 142:70-78.
21. Didier A., Malling H.J., Worm M., Horak F., Sussman G., Melac M., et al. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin Exp Allergy 2013, 43:568-577.
22. Ariano R., Kroon A.M., Augeri G., Canonica G.W., Passalacqua G. Long-term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial. Allergy 1999, 54:313-319.
23. Des Roches A., Paradis L., Menardo J.L., Bouges S., Daures J.P., Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. JAllergy Clin Immunol 1997, 99:450-453.
24. Jacobsen L., Niggemann B., Dreborg S., Ferdousi H.A., Halken S., Host A., et al. Specific immunotherapy has long-term preventive effect of seasonal andperennial asthma: 10-year follow-up on the PAT study. Allergy 2007, 62:943-948.
25. Niggemann B., Jacobsen L., Dreborg S., Ferdousi H.A., Halken S., Host A., et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 2006, 61:855-859.
26. Moller C., Dreborg S., Ferdousi H.A., Halken S., Host A., Jacobsen L., et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). JAllergy Clin Immunol 2002, 109:251-256.
27. Polosa R., Li Gotti F., Mangano G., Paolino G., Mastruzzo C., Vancheri C., et al. Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis. Allergy 2004, 59:1224-1228.
28. Novembre E., Galli E., Landi F., Caffarelli C., Pifferi M., De Marco E., et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. JAllergy Clin Immunol 2004, 114:851-857.
29. Marogna M., Tomassetti D., Bernasconi A., Colombo F., Massolo A., Businco A.D., et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol 2008, 101:206-211.
30. Purello-D'Ambrosio F., Gangemi S., Merendino R.A., et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001, 31:1295-1302.
31. Pajno G.B., Barberio G., De Luca F., Morabito L., Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001, 31:1392-1397.
32. Reha C.M., Ebru A. Specific immunotherapy is effective in the prevention of new sensitivities. Allergol Immunopathol (Madr) 2007, 35:44-51.
33. Gulen F., Zeyrek D., Can D., Altinoz S., Koksoy H., Demir E., et al. Development of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. Asian Pac J Allergy Immunol 2007, 25:7-11.
34. Marogna M., Spadolini I., Massolo A., Canonica G.W., Passalacqua G. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy 2004, 59:1205-1210.
35. Marogna M., Falagiani P., Bruno M., Massolo A., Riva G. The allergic march in pollinosis: natural history and therapeutic implications. Int Arch Allergy Immunol 2004, 135:336-342.
36. Hankin C.S., Cox L., Lang D., Levin A., Gross G., Eavy G., et al. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. JAllergy Clin Immunol 2008, 121:227-232.
37. Donahue J.G., Greineder D.K., Connor-Lacke L., Canning C.F., Platt R. Utilization and cost of immunotherapy for allergic asthma and rhinitis. Ann Allergy Asthma Immunol 1999, 82:339-347.
38. Law A.W., Reed S.D., Sundy J.S., Schulman K.A. Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey. JAllergy Clin Immunol 2003, 111:296-300.
39. Bender B.G., Oppenheimer J. The special challenge of nonadherence with sublingual immunotherapy. JAllergy Clin Immunol Pract 2014, 2:152-155.
40. Cohn J.R., Pizzi A. Determinants of patient compliance with allergen immunotherapy. JAllergy Clin Immunol 1993, 91:734-737.
41. Lower T., Henry J., Mandik L., Janosky J., Friday G.A. Compliance with allergen immunotherapy. Ann Allergy 1993, 70:480-482.
42. Sade K., Berkun Y., Dolev Z., Shalit M., Kivity S. Knowledge and expectations of patients receiving aeroallergen immunotherapy. Ann Allergy Asthma Immunol 2003, 91:444-448.
43. Sangasapaviliya A., Pholsuwanchai K. Attitude and knowledge of patients with asthma and allergic rhinitis who received allergen immunotherapy in Phramongkutklao Hospital. JMed Assoc Thai 2010, 93(Suppl 6):S100-S105.
44. Mabry R.L. Desensitization versus intraturbinal injection of corticosteroid for nasal allergy: indications, effectiveness, and patient acceptance. South Med J 1982, 75:423-425.
45. Rhodes B.J. Patient dropouts before completion of optimal dose, multiple allergen immunotherapy. Ann Allergy Asthma Immunol 1999, 82:281-286.
46. More D.R., Hagan L.L. Factors affecting compliance with allergen immunotherapy at a military medical center. Ann Allergy Asthma Immunol 2002, 88:391-394.
47. Dam Petersen K., Gyrd-Hansen D., Kjaergaard S., Dahl R. Clinical and patient based evaluation of immunotherapy for grass pollen and mite allergy. Allergol Immunopathol (Madr) 2005, 33:264-269.
48. Tinkelman D., Smith F., Cole W.Q., Silk H.J. Compliance with an allergen immunotherapy regime. Ann Allergy Asthma Immunol 1995, 74:241-246.
49. Pajno G.B., Vita D., Caminiti L., Arrigo T., Lombardo F., Incorvaia C., et al. Children's compliance with allergen immunotherapy according to administration routes. JAllergy Clin Immunol 2005, 116:1380-1381.
50. Mahesh P.A., Vedanthan P.K., Amrutha D.H., Giridhar B.H., Prabhakar A.K. Factors associated with non-adherence to specific allergen immunotherapy in management of respiratory allergy. Indian J Chest Dis Allied Sci 2010, 52:91-95.
51. Hsu N.M., Reisacher W.R. Acomparison of attrition rates in patients undergoing sublingual immunotherapy vs subcutaneous immunotherapy. Int Forum Allergy Rhinol 2012, 2:280-284.
52. Sieber J., De Geest S., Shah-Hosseini K., Mosges R. Medication persistence with long-term, specific grass pollen immunotherapy measured by prescription renewal rates. Curr Med Res Opin 2011, 27:855-861.
53. Ruiz F.J., Jimenez A., Cocoletzi J., Duran E. Compliance with and abandonment of immunotherapy [in Spanish with English abstract]. Rev Alerg Mex 1997, 44:42-44.
54. Chang H., Han D.H., Mo J.H., Kim J.W., Kim D.Y., Lee C.H., et al. Early compliance and efficacy of sublingual immunotherapy in patients with allergic rhinitis for house dust mites. Clin Exp Otorhinolaryngol 2009, 2:136-140.
55. Senna G., Lombardi C., Canonica G.W., Passalacqua G. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. JAllergy Clin Immunol 2010, 126:668-669.
56. Trebuchon F., David M., Demoly P. Medical management and sublingual immunotherapy practices in patients with house dust mite-induced respiratory allergy: a retrospective, observational study. Int J Immunopathol Pharmacol 2012, 25:193-206.
57. Kiel M.A., Roder E., Gerth van Wijk R., Al M.J., Hop W.C., Rutten-van Molken M.P. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. JAllergy Clin Immunol 2013, 132. 353-60.e2.
58. Incorvaia C., Rapetti A., Scurati S., Puccinelli P., Capecce M., Frati F. Importance of patient's education in favouring compliance with sublingual immunotherapy. Allergy 2010, 65:1341-1342.
59. Pajno G.B., Caminiti L., Crisafulli G., Barberi S., Landi M., Aversa T., et al. Adherence to sublingual immunotherapy in preschool children. Pediatr Allergy Immunol 2012, 23:688-689.
60. Vita D., Caminiti L., Ruggeri P., Pajno G.B. Sublingual immunotherapy: adherence based on timing and monitoring control visits. Allergy 2010, 65:668-669.
61. Ott H., Sieber J., Brehler R., Folster-Holst R., Kapp A., Klimek L., et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 2009, 64:1394-1401.
62. Scurati S., Frati F., Passalacqua G., Puccinelli P., Hilaire C., Incorvaia C., et al. Adherence issues related to sublingual immunotherapy as perceived by allergists. Patient Pref Adherence 2010, 4:141-145.
63. Roder E., Berger M.Y., de Groot H., Gerth van Wijk R Sublingual immunotherapy in youngsters: adherence in a randomized clinical trial. Clin Exp Allergy 2008, 38:1659-1667.
64. Jansen A., Andersen K.F., Bruning H. Evaluation of a compliance device in a subgroup of adult patients receiving specific immunotherapy with grass allergen tablets (GRAZAX) in a randomized, open-label, controlled study: an a priori subgroup analysis. Clin Ther 2009, 31:321-327.
65. Durham S.R., Yang W.H., Pedersen M.R., Johansen N., Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. JAllergy Clin Immunol 2006, 117:802-809.
66. Passalacqua G., Musarra A., Pecora S., Amoroso S., Antonicelli L., Cadario G., et al. Quantitative assessment of the compliance with a once-daily sublingual immunotherapy regimen in real life (EASY Project: Evaluation of A novel SLIT formulation during a Year). JAllergy Clin Immunol 2006, 117:946-948.
67. Passalacqua G., Musarra A., Pecora S., Amoroso S., Antonicelli L., Cadario G., et al. Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY project: evaluation of a novel SLIT formulation during a year). Pediatr Allergy Immunol 2007, 18:58-62.
68. Halken S., Agertoft L., Seidenberg J., Bauer C.P., Payot F., Martin-Munoz M.F., et al. Five-grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents. Pediatr Allergy Immunol 2010, 21:970-976.
69. Bufe A., Eberle P., Franke-Beckmann E., Funck J., Kimmig M., Klimek L., et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. JAllergy Clin Immunol 2009, 123. 167-73.e7.
70. Lombardi C., Gani F., Landi M., Falagiani P., Bruno M., Canonica G.W., et al. Quantitative assessment of the adherence to sublingual immunotherapy. JAllergy Clin Immunol 2004, 113:1219-1220.
71. Wahn U., Tabar A., Kuna P., Halken S., Montagut A., deBeaumont O., et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. JAllergy Clin Immunol 2009, 123. 160-6.e3.
72. Shaikh W.A., Shaikh S.W. Allergies in India: a study on medication compliance. JIndian Med Assoc 2009, 107:462-463.
73. Migueres M., Fontaine J.F., Haddad T., Grosclaude M., Saint-Martin F., BemDavid D., et al. Characteristics of patients with respiratory allergy in France and factors influencing immunotherapy prescription: a prospective observational study (REALIS). Int J Immunopathol Pharmacol 2011, 24:387-400.
74. Vaswani R., Liu Y.C., Parikh L., Vaswani S. Inadequate health insurance coverage: a major factor in premature discontinuation of subcutaneous immunotherapy for allergic rhinitis. Ear Nose Throat J 2011, 90:170-173.
75. Marti E., Sanchez-Salguero C., Scorza E., Alberto Garcia M. Longer treatment duration with SLIT leads to higher patient satisfaction and clinical improvement. Outcomes of the SAMITES study. Clinical Transl Allergy 2013, (Suppl 2):P12.
76. Hommers L., Ellert U., Scheidt-Nave C., Langen U. Factors contributing to conductance and outcome of specific immunotherapy: data from the German National Health Interview and Examination Survey 1998. Eur J Public Health 2007, 17:278-284.
77. Marogna M., Spadolini I., Massolo A., Canonica G.W., Passalacqua G. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy 2004, 59:1205-1210.
78. Marogna M., Tomassetti D., Bernasconi A., Colombo F., Massolo A., Businco A.D., et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol 2008, 101:206-211.
79. Roder E., Berger M.Y., de Groot H. Gerth van Wijk R. Sublingual immunotherapy in youngsters: adherence in a randomized clinical trial. Clin Exp Allergy 2008, 38:1659-1667.
80. Ott H., Sieber J., Brehler R., Folster-Holst R., Kapp A., Klimek L., et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT Study. Allergy 2009, 64:1394-1401.
81. Scurati S., Frati F., Passalacqua G., Puccinelli P., Hilaire C., Incorvaia C., et al. Adherence issues related to sublingual immunotherapy as perceived by allergists. Patient Prefer Adherence 2010, 4:141-145.
82. Pajno G.B., Caminiti L., Crisafulli G., Barberi S., Landi M., Aversa T., et al. Adherence to sublingual immunotherapy in preschool children. Pediatr Allergy Immunol 2012, 23:688-689.
83. Kiel M.A., Roder E., Gerth van Wijk R., Al M.J., Hop W.C., Rutten-van Molken M.P. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. JAllergy Clin Immunol 2013, 132. 353-60.e2.
84. Lombardi C., Gani F., Landi M., Falagiani P., Bruno M., Canonica G.W., et al. Quantitative assessment of the adherence to sublingual immunotherapy. JAllergy Clin Immunol 2004, 113:1219-1220.
85. Jansen A., Andersen K.F., Bruning H. Evaluation of a compliance device in a subgroup of adult patients receiving specific immunotherapy with grass allergen tablets (GRAZAX) in a randomized, open-label, controlled study: an a priori subgroup analysis. Clin Ther 2009, 31:321-327.
86. Durham S.R., Yang W.H., Pedersen M.R., Johansen N., Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. JAllergy Clin Immunol 2006, 117:802-809.
87. Passalacqua G., Musarra A., Pecora S., Amoroso S., Antonicelli L., Cadario G., et al. Quantitative assessment of the compliance with a once-daily sublingual immunotherapy regimen in real life (EASY Project: Evaluation of A novel SLIT formulation during a Year). JAllergy Clin Immunol 2006, 117:946-948.
88. Passalacqua G., Musarra A., Pecora S., Amoroso S., Antonicelli L., Cadario G., et al. Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY project: evaluation of a novel SLIT formulation during a year). Pediatr Allergy Immunol 2007, 18:58-62.
89. Cadario G., Ciprandi G., Di Cara G., Fadel R., Incorvaia C., Marcucci F., et al. Comparison between continuous or intermittent schedules of sublingual immunotherapy for house dust mites: effects on compliance, patients satisfaction, quality of life and safety. Int J Immunopathol Pharmacol 2008, 21:471-473.
90. Bufe A., Eberle P., Franke-Beckmann E., Funck J., Kimmig M., Klimek L., et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. JAllergy Clin Immunol 2009, 123. 167-73.e7.
91. Shaikh W.A., Shaikh S.W. Allergies in India: a study on medication compliance. JIndian Med Assoc 2009, 107:462-463.
92. Wahn U., Tabar A., Kuna P., Halken S., Montagut A., deBeaumont O., et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. JAllergy Clin Immunol 2009, 123. 160-6.e3.
93. Halken S., Agertoft L., Seidenberg J., Bauer C.P., Payot F., Martin-Munoz M.F., et al. Five-grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents. Pediatr Allergy Immunol 2010, 21:970-976.
94. Migueres M., Fontaine J.F., Haddad T., Grosclaude M., Saint-Martin F., BemDavid D., et al. Characteristics of patients with respiratory allergy in France and factors influencing immunotherapy prescription: a prospective observational study (REALIS). Int J Immunopathol Pharmacol 2011, 24:387-400.
95. Cohn J.R., Pizzi A. Determinants of patient compliance with allergen immunotherapy. JAllergy Clin Immunol 1993, 91:734-737.
96. Lower T., Henry J., Mandik L., Janosky J., Friday G.A. Compliance with allergen immunotherapy. Ann Allergy 1993, 70:480-482.
97. Rhodes B.J. Patient dropouts before completion of optimal dose, multiple allergen immunotherapy. Ann Allergy Asthma Immunol 1999, 82:281-286.
98. More D.R., Hagan L.L. Factors affecting compliance with allergen immunotherapy at a military medical center. Ann Allergy Asthma Immunol 2002, 88:391-394.
99. Mabry R.L. Desensitization versus intraturbinal injection of corticosteroid for nasal allergy: indications, effectiveness, and patient acceptance. South Med J 1982, 75:423-425.
100. Pajno G.B., Vita D., Caminiti L., Arrigo T., Lombardo F., Incorvaia C., et al. Children's compliance with allergen immunotherapy according to administration routes. JAllergy Clin Immunol 2005, 116:1380-1381.
101. Hsu N.M., Reisacher W.R. Acomparison of attrition rates in patients undergoing sublingual immunotherapy vs subcutaneous immunotherapy. Int Forum Allergy Rhinol 2012, 2:280-284.
102. Vaswani R., Liu Y.C., Parikh L., Vaswani S. Inadequate health insurance coverage: a major factor in premature discontinuation of subcutaneous immunotherapy for allergic rhinitis. Ear Nose Throat J 2011, 90:170-173.
103. Ruiz F.J., Jimenez A., Cocoletzi J., Duran E. Compliance with and abandonment of immunotherapy [in Spanish with English abstract]. Rev Alerg Mex 1997, 44:42-44.
104. Chang H., Han D.H., Mo J.H., Kim J.W., Kim D.Y., Lee C.H., et al. Early compliance and efficacy of sublingual immunotherapy in patients with allergic rhinitis for house dust mites. Clin Exp Otorhinolaryngol 2009, 2:136-140.
105. Trebuchon F., David M., Demoly P. Medical management and sublingual immunotherapy practices in patients with house dust mite-induced respiratory allergy: a retrospective, observational study. Int J Immunopathol Pharmacol 2012, 25:193-206.